Demonstration of proof-of-concept in an animal model of type 2 diabetes and obesity clearly requires the identification of a stable compound that is more effective as an agonist of CMKLR1. The gene discussed is CMKLR1; the disease is obesity due to melanocortin 4 receptor deficiency.